Neurology focus

The challenges
The inaccessibility of the brain and the relative scarcity of definitive physical parameters for clinical evaluation represent major challenges when it comes to neurological conditions such as neurodegenerative diseases and chronic pain. A better understanding of the biology and the underlying pathophysiology is also required. It is important to search for better fluid-based biomarkers that give physicians effective decision making tools. There is a need for easily accessible biomarkers that can diagnose and stratify patients as well as signal when patients respond to treatment (1). Neurodegenerative diseases in particular, are also expected to increase in prevalence as people live longer than ever before.

Protein biomarkers
Although advances in brain imaging offer improved diagnostics, fluid-based biomarkers could reflect the broad range of biological activities. There is an urgent need to identify proteins that will assist in patient diagnosis that correlate with the biological response to different diseases, which can be easily measured in a non-invasive manner from samples such as peripheral blood. In the neurology field, it can also be important to examine other specialized sample matrices such as cerebrospinal fluid (CSF), brain tissue lysates or microdialysis samples. Here we will briefly review how Olink’s multiplexed protein biomarker panels can address some of these issues.

Olink® technology
The proximity extension assay (PEA) successfully merges a dual-recognition immunoassay that employs pairs of matched antibodies linked to unique DNA oligonucleotides for readout by quantitative real-time PCR (qPCR), this results in a multiplexable and highly specific method where only 1 µL of sample is needed to quantify up to 92 protein biomarkers simultaneously (2). Multiple 92-plex panels are available, covering a range of disease areas and biological processes. The figure shows the four different steps of the PEA technology.

Olink offers a broad range of protein biomarker discovery and validation tools, as fee-for-service or kits to run in your own lab.

Olink NEUROLOGY, for example, is designed specifically for research in the neurology area, but can be complimented with other highly relevant panels such as those focused on inflammation or oncology.

Olink NEURO EXPLORATORY includes a combination of exploratory and established markers with a focus on neurology-related diseases, and biological processes such as axon development, neurogenesis and synapse assembly. The established proteins include Neurofilament light* with a performance comparable to gold-standard low-plex assays.

Correlation versus Simoa in 90 plasma samples

*Uses the NF-light® antibodies from UmanDiagnostics, Umeå, Sweden
Samples were supplied by courtesy of Prof. Tomas Olsson (KI, Sweden)

Example studies
Lumbar radicular pain
Studies suggest that disc herniation may be associated with an upregulation of several inflammatory molecules.
One study demonstrated an inflammatory fingerprint in the serum of patients with persistent lumbar radicular pain after disc herniation (3). This fingerprint, determined using Olink technology, clearly stratified patients who did or did not develop chronic pain following surgery. This evidence enables an objective, measurable approach to a condition that is otherwise largely dependent on subjective input from patients, and giving their condition more clinical dignity. This approach could be important for future protein serum profiling of chronic pain patients with regard to prognosis and choice of treatment.

Postpartum depression
The adaptive change in the immune system function during a pregnancy sometimes causes increased levels of inflammation biomarkers in late pregnancy. According to a case-control study these biomarkers might be associated with postpartum depression. The Olink analysis enabled the screening of a wide range of inflammatory biomarkers where several that differed between groups represented novel findings (4).

Traumatic brain injury
When it comes to traumatic brain injury (TBI), it is important with an early diagnosis. One study used Olink to find biomarkers connected to different stages of TBI. The correct diagnosis of TBI, which can be a challenging diagnosis to make, would allow clinicians to implement strategies to reduce secondary brain injury at an early stage. Here, the protein CST5 was shown to be an ideal ultra-early biomarker with the ability to not only determine the presence of the condition but also discriminate between TBI severities (5).

Alzheimer's disease
In another study, Olink was used to compare low abundance proteins in CSF of Alzheimer's disease (AD) patients and healthy controls. Initial comparisons between AD and controls indicated that many proteins were decreased in AD. Several novel candidate biomarkers emerged that differ between AD and controls, for example CD200 and WIF-1. Analysis of longitudinal CSF samples showed a decrease in the concentration of many proteins over 12 months (6).

Olink for neurology research
- Only 1 µL is needed to measure 92 proteins simultaneously
- A range of compatible sample types such as plasma, serum, CSF, brain tissue lysates and micro-dialysis fluid
- Around 1000 validated protein assays available in disease and biological process focused panels
- Includes validated and exploratory biomarkers for neurology research

Read more
PEA technology: [www.olink.com/technology](http://www.olink.com/technology)
Protein panels and complete biomarker list: [www.olink.com/products](http://www.olink.com/products)
Publications: [www.olink.com/publications](http://www.olink.com/publications)
FAQ: [www.olink.com/faq](http://www.olink.com/faq)

References

For research use only. Not for use in diagnostic procedures. This product includes a license for non-commercial use. Commercial users may require additional licenses. Please contact Olink Proteomics AB for details. There are no warranties, expressed or implied, which extend beyond this description. Olink Proteomics AB is not liable for property damage, personal injury, or economic loss caused by this product. Olink® is a registered trademark of Olink Proteomics AB. © 2018 Olink Proteomics AB. All third party trademarks are the property of their respective owners.